May And July

In May, Plavix patent expires

In May, Plavix patent expires. This month, the world's second-largest selling drug Plavix had its patent expired in the United States. Plavix is developed by Sanofi, first approved in the United States market in 1997. Sanofi is responsible for the drug market sales outside the United States, and Bristol-Myers Squibb is responsible for the sales of the U.S. market. In 2011, Plavix had an contribution of $ 7.1 billion in sales for Bristol-Myers Squibb. Comments: This year, there are more than 40 brand-name drugs lose patent protection, and these drugs have annual sales of over 35 billion U.S. dollars. Currently, generic drug is account for about 80% share of the U.S. pharmaceutical market. Due to the great competition in the generic drugs, Bristol-Myers and their partner Sanofi announced no longer develop promotional plans of Plavix. The lose of patent protection for Plavix is a great blow to Bristol-Myers Squibb. To supply the product line of research and development, dealing with economic losses caused by Plavixs patent expires, Bristol-Myers Squibb launched a medium-sized M & A action named the "string of pearls", which includes the $ 5.3 billion cash acquisition of Amylin Pharmaceuticals, biotechnological company. In July, EMA opens the clinical trial database. The European Medicines Agency (EMA) officially opened its database for a systematic review, which allows independent researchers have access to millions of copies of the clinical trial data. In the past year and a half, EMA announced more than 150 million pages of data from clinical trials, and has significantly increased compared to the data published between 2009 and 2010. Review: Previously, the pharmaceutical industry considers for strictly commercial secrets, and never be required to share data with researchers. But now you have to supply the data to get drugs approval submitted to the EMA . The large number of clinical trial data published by EMA will help researchers review of clinical trials in the past, but also conducive to new drug development. The EMA movement let Europe prior to the U.S. opening clinical trial data, and both have been criticized by failing to find drugs risks, such as Vioxx and cultural Avandia event. However, EMA is not voluntarily disclose data, but is advanced by the public pressure. In the past, the clinical trial data are highly confidential and need to purchase. This is on the contrary to the interests of the public.

by: DJDROGBA

POST COMMENT

Necessary For Nri Pan Card And How To Apply Correctng Americas Obesity And Financial Problems Let Your Eyelashes Grow Thicker And Fuller With Best Eyelash Growth Product! Recommendations And Ideas For Handling Your Skin Care Issues Quick Payday Loans: Safe, Secure And Simple Payday Loan Making Boats And Plywood Kerala Sex And Mallu Girls Rustic Interiors Keep It Rustic, Warm And Basic The Best And Cheapest Football Boots Are At Pesoccerworld Get Rid Of Dark Circles And Small Lashes With Effective Treatment! An Evaluation Of Methods Of Antique And Present Day Paintings Soccerpro2013: Soccer Cleats And More Bpo Jobs In Delhi- American Timings And American Style